OnabotulinumtoxinA in Migraine: A Review of the Literature and Factors Associated with Efficacy.
Jason Charles RayElspeth Jane HuttonManjit Singh MatharuPublished in: Journal of clinical medicine (2021)
The efficacy of onabotulinumtoxinA (OnaB-A) as a preventative treatment for chronic migraine, emerging fortuitously from clinical observation is now supported by class one evidence and over two decades of real-world clinical data. There is still limited ability to predict a clinically meaningful response to OnaB-A for individual patients, however. This review summarises briefly the proposed mechanism of OnaB-A in chronic migraine, the literature of predictors of clinical response, and recent developments in the field.